Astellas Pharma Inc.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 14 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Top Mutual Funds / ETFs
Updated 2026/01/11Major Holders
Updated 2026/01/11| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
26.0M | +0.15% | |
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
23.0M | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
16.5M | +2.67% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
12.3M | +1.36% | |
|
Fidelity Concord Street Trust-Fidelity International Index Fund
|
6.4M | -0.16% | |
|
iShares, Inc.-iShares MSCI Japan ETF
|
6.3M | +0.96% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
1.1M | +2.00% | |
|
Paradigm Asset Management Company, LLC
|
5.1K | 0.00% |
Dividend History 4Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥76 | +5.6% |
| 2024 | ¥72 | +10.8% |
| 2023 | ¥65 | +18.2% |
| 2022 | ¥55 | +19.6% |
| 2021 | ¥46 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,296,163M | ¥1,518,619M | ¥1,603,672M | ¥1,912,323M |
| Gross Profit | ¥1,043,154M | ¥1,230,266M | ¥1,311,187M | ¥1,563,117M |
| Operating Income | ¥130,963M | ¥131,557M | ¥18,947M | ¥40,248M |
| Pretax Income | ¥161,835M | ¥141,140M | ¥36,974M | ¥48,914M |
| Net Income | ¥124,086M | ¥98,714M | ¥17,045M | ¥50,747M |
| EPS | ¥67.05 | ¥54.09 | ¥9.47 | ¥28.24 |
| Operating Margin | 10.10% | 8.66% | 1.18% | 2.10% |
| Balance Sheet | ||||
| Total Assets | ¥2,332,395M | ¥2,456,518M | ¥3,569,603M | ¥3,339,544M |
| Total Equity | ¥1,460,308M | ¥1,507,954M | ¥1,595,988M | ¥1,513,255M |
| Total Liabilities | ¥872,087M | ¥948,564M | ¥1,973,615M | ¥1,826,289M |
| Cash | ¥315,986M | ¥376,840M | ¥335,687M | ¥188,372M |
| Interest-bearing Debt | - | ¥125,000M | ¥920,016M | ¥831,426M |
| Equity Ratio | 62.61% | 61.39% | 44.71% | 45.31% |
| D/E Ratio | 0.00 | 0.08 | 0.58 | 0.55 |
| Cash Flow | ||||
| Operating CF | ¥257,444M | ¥327,767M | ¥172,475M | ¥194,512M |
| Investing CF | -¥62,413M | -¥84,500M | -¥845,802M | -¥89,419M |
| Financing CF | -¥216,298M | -¥195,623M | ¥614,060M | -¥261,367M |
| Free CF | ¥180,996M | ¥239,226M | ¥89,978M | ¥137,182M |
| Efficiency | ||||
| ROE | 8.50% | 6.55% | 1.07% | 3.35% |
| ROA | 5.32% | 4.02% | 0.48% | 1.52% |
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥1,885
Rating Score: 2.38 (Based on 14 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressants. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize an integrated diabetes self-management solution. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
